Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

78.48 +0.55 (+0.71%)
Streaming Delayed Price Updated: 10:54 AM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability. 
Via Chartmill
News headline image
NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
NASDAQ:HALO, an undervalued stock with good fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
News headline image
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Earnings Outlook For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗
NASDAQ:HALO, a growth stock which is not overvalued. 
Via Chartmill
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune ↗
Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune. 
Via InvestorPlace
News headline image
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or... 
Via Benzinga
News headline image
NASDAQ:HALO is showing decent growth, but is still valued reasonably. ↗
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO). 
Via Chartmill
News headline image
Analyst Expectations for Halozyme Therapeutics's Future ↗
 
Via Benzinga
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Where Halozyme Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Expert Ratings for Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout. 
Via Chartmill
News headline image
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall ↗
Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment. 
Via InvestorPlace
News headline image
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
News headline image
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market ↗
HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗
 
Via Benzinga
News headline image
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
Via Benzinga
News headline image
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs ↗
The surge of artificial intelligence (AI) is sparking a transformative shift in the relative valuations of prominent U.S. stock averages as the tech sector outperforms other industries and small-cap... 
Via Benzinga
News headline image
7 Meme Stocks to Buy Before They Soar to New Heights in 2023 ↗
Investing in meme stocks is no longer about driving dying companies higher. In fact, let’s get into meme-worthy and investment-grade shares. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.